-
Bayer Faces Backlash After Bond Sale Preceding Late-Stage Pipeline Failure
•
German pharmaceutical giant Bayer (ETR: BAYN) is facing investor and analyst scrutiny following its issuance of USD 5.75 billion in bonds shortly before disclosing a significant setback in its late-stage pipeline. The company issued the 3 to 30-year maturity bonds on November 16, and then announced the early termination of…
-
Everest Medicines’ Nefecon for IgAN Receives NMPA Approval in China
•
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that its New Drug Application (NDA) for Nefecon (targeted-release formulation budesonide) for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression has been approved by the National Medical Products Administration (NMPA). Nefecon is a…
-
Beijing QL Biopharmaceutical Boosts Pipeline with RMB 200 Million Series B+ Round
•
Beijing QL Biopharmaceutical Co., Ltd., a Chinese biopharmaceutical company, has reportedly secured nearly RMB 200 million (USD 28 million) in a Series B+ financing round. The round was led by IMEIK Technology and China-US Green Fund, with additional investments from Jiayuan Fund, Chengdu Capital Group, Lanchi Ventures, and other parties.…
-
Henlius Biotech Gets FDA Clearance for Clinical Study of PD-L1 Targeting ADC HLX43
•
Shanghai Henlius Biotech Inc. (HKG: 2696), a Chinese biopharmaceutical company, has received approval from the US Food and Drug Administration (FDA) to conduct a clinical study for its antibody drug conjugate (ADC) HLX43, which is co-developed with Suzhou-based Medilink Therapeutics. The molecule is set to be evaluated in patients with…
-
CSPC Pharmaceutical Gets NMPA Green Light for SYH2038 Solid Tumor Study
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a Chinese pharmaceutical company, has announced that it has received approval from the National Medical Products Administration (NMPA) to initiate a clinical study for its Category 1 chemical drug, SYH2038, in advanced solid tumors. SYH2038 is a highly selective SOS1 inhibitor, with no similar…
-
Abbisko Therapeutics Launches Phase II Trial for Pimocitinib in Advanced Pancreatic Cancer
•
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced the initiation of a Phase II clinical study for its Category 1 innovative drug ABSK021 (pimicotinib) in advanced pancreatic cancer in China, with the first patient now dosed. The multi-center, open-label Phase II study (ABSK021-202) is being conducted…
-
Xiamen Inno Medical Partners with Olympus to Advance AI in Digestive Endoscopy
•
Xiamen Inno Medical Technology Co., Ltd., a China-based specialist in artificial intelligence (AI) powered digestive endoscopy, has entered into a partnership with Olympus Corporation, a major player in the digestive endoscopy field. The collaboration aims to explore innovative applications and development of AI technology within the digestive endoscopy sector. Financial…
-
Jenscare Reports Positive One-Year Outcomes for LuX-Valve in Tricuspid Valve Replacement Study
•
Jenscare Scientific Co., Ltd. (HKG: 9877), a Ningbo-based manufacturer of devices for structural heart disease, has released promising one-year results from a confirmatory study of its transcatheter tricuspid valve replacement system, LuX-Valve. The prospective, multi-center, single-arm study aimed to evaluate the safety and efficacy of the LuX-Valve in patients suffering…
